# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Satchel Paige (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML047-SYN-TD
- Date: 1979-07-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Delphine Whitaker-Osei, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for establishing primary care for two years of breathlessness on exertion and a morning cough: history, examination, blood tests including alpha-1 antitrypsin and eosinophils, ECG, NT-proBNP, cardiovascular risk, vaccines, a reliever inhaler and a pulmonology consultation. **S**

## Objective

Hemoglobin: 15.2 g/dL; White blood cells: 7.1 10*3/uL; Eosinophils (absolute): 0.08 10*3/uL; Alpha-1 antitrypsin: 142 mg/dL; Sodium: 140 mmol/L; Potassium: 4.3 mmol/L; Creatinine: 1.08 mg/dL; eGFR (CKD-EPI 1974, race-free): 71 mL/min/1.73 m²; Glucose: 96 mg/dL; HbA1c: 5.6%; ALT: 21 U/L; Total cholesterol: 224 mg/dL (high); HDL cholesterol: 44 mg/dL; LDL cholesterol (calculated): 148 mg/dL (high); Triglycerides: 160 mg/dL (high); NT-proBNP: 92 pg/mL; PHQ-9: 5; AUDIT-C: 1. All results are synthetic.

BP 136/82 mmHg; pulse 84 bpm; respirations 18/min; temperature 36.7 °C; oxygen saturation 94% on room air; weight 82.6 kg; BMI 22.6 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Breathlessness on exertion for about two years, now after one flight of stairs or a block on the level (mMRC 2), with a morning cough and a little clear sputum most days; no chest pain, ankle swelling, orthopnea, wheeze at rest or weight loss; a former smoker of about 30 pack-years; cause under evaluation with spirometry and a pulmonology consultation; Former cigarette smoker, about 30 pack-years, stopped eleven years ago on his own; no use since; Hyperlipidemia: LDL 148 mg/dL, HDL 44 and triglycerides 160 at intake; estimated 10-year cardiovascular risk about 18 percent; atorvastatin started by shared decision. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Started: Albuterol 90 micrograms per inhalation metered-dose inhaler with a spacer, two inhalations every four hours as needed for breathlessness **S**
- Started: Atorvastatin 20 mg tablet once a day **S**

## Plan

- Breathlessness work-up at intake: symptoms with the CAT and mMRC, exacerbation history over the past year, smoking history and examination; blood count with eosinophils, alpha-1 antitrypsin once, kidney function, HbA1c, lipids, NT-proBNP and a 12-lead ECG; resting oxygen saturation read with care in darker skin. Guideline: Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025); Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement (2023); CMID: Clinical Monitoring Intelligence Database, COPD and hyperlipidemia monographs (2026) **S**
- Pulmonology consultation to confirm the diagnosis with spirometry, interpret it with race-neutral equations, and advise on treatment, oxygen and rehabilitation. Guideline: Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025); Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement (2023) **S**
- Albuterol with a spacer as needed for breathlessness, with technique checked at the visit. Guideline: Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025) **S**
- Cardiovascular risk: moderate-intensity atorvastatin by shared decision, with a lipid panel at about eight weeks; blood pressure at each visit; ECG reviewed after any exacerbation. Guideline: Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025); Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022) **S**
- Vaccines: PCV20 and Tdap now; influenza, RSV and COVID-19 in the autumn; recombinant zoster. Guideline: Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025); Adult Immunization Schedule by Age (2026) **S**
